Industry
Biotechnology
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
April 26, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Newsdesk
April 18, 2024 | 4:36 pm
Portfolio Pulse from Benzinga Newsdesk
April 18, 2024 | 1:23 pm
Portfolio Pulse from Benzinga Newsdesk
April 08, 2024 | 10:11 am
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 1:33 pm
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 12:22 pm
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 10:26 am
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 10:19 am
Portfolio Pulse from Benzinga Insights
March 22, 2024 | 5:31 pm
Portfolio Pulse from Benzinga Insights
December 18, 2023 | 9:31 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.